Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor model based on the published strategy ...

Weight loss drugmaker Novo Nordisk (NVO) on Friday announced that its CEO, Lars Fruergaard Jørgensen, will resign from his leadership role as the company searches for his successor. NVO said that ...

As of mid-morning trading, the tech-heavy Nasdaq Composite is on pace for a ... Novo Nordisk (NYSE: NVO), the maker of the weight loss drug Wegovy, fell as much as 5% amid an executive shakeup.

Mike Novogratz's crypto firm Galaxy Digital started trading on the Nasdaq on Friday under the ticker GLXY. The stock opened at $23.50 per share on the U.S. exchange. Galaxy Digital, which has been ...

The billionaire crypto mogul rang the opening bell at the Nasdaq Friday under the ticker GLXY with his company trading on U.S. public markets for the first time in a direct listing. Novogratz said ...

The markets have erased most of their earlier losses from this morning, with the Dow Jones Industrial Average and S&P 500 now positive while the Nasdaq Composite is seeing a slight decline.

The Nasdaq has advanced more than 20% from its recent low -- it must record a new high to enter bull territory. Investors are returning to growth stocks as the risk of high import tariffs ...

Jhonattan Vegas wears it on the left side of his polo, and others have the logo elsewhere on their clothing. It sits in a place not uncommon for sponsors, but it seems like a strange thing to ...

Spencer Platt / Getty Images Big gains for big-name technology stocks on Wednesday pushed the Nasdaq Composite to its sixth consecutive winning session, while the benchmark S&P 500 managed to ...

eToro Group Ltd. saw its stock generate a 29% gain over its upped IPO price at the closing bell on Wednesday, in a strong trading debut for the mobile stock- and crypto-trading firm in one of the ...

Septerna (NASDAQ:SEPN) climbed ~63% in the premarket on Wednesday after the Wegovy maker Novo Nordisk (NVO) agreed to jointly develop and commercialize oral small-molecule drugs for obesity and ...

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...